Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers

Cancer Treatment Reviews

Volumn 43, Issue , 2016, Pages 1-7

  Musolino, Antonino ^a   Boggiani, Daniela ^a   Sikokis, Angelica ^a   Rimanti, Anita ^a   Pellegrino, Benedetta ^a   Vattiato, Rosa ^b   Sgargi, Paolo ^a   Falcini, Fabio ^b   Caminiti, Caterina ^a   Michiara, Maria ^a   Leonardi, Francesco ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

Breast cancer; HER2 positive; Interval cancer risk; Prognostic factors; PT1a,b

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; KI 67 ANTIGEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

AGE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; HER2 POSITIVE BREAST CANCER; HUMAN; INTERVAL CANCER DETECTION; LYMPH VESSEL METASTASIS; MEDICAL DECISION MAKING; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CLINICAL DECISION MAKING; DIAGNOSIS; DISEASE FREE SURVIVAL; FEMALE; METABOLISM; PATHOLOGY; PREVENTION AND CONTROL; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL DECISION-MAKING; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RISK ASSESSMENT; RISK FACTORS; TRASTUZUMAB;

EID: 84962033872     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.11.010     Document Type: Review

References (68)

1. U.S.Preventive Services Task Force Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009, 151:716-726.
2. Bucchi L., Falcini F., Baraldi G.P., Bondi A., Bonsanto R., Bravetti P., et al. Integrating self-referral for mammography into organised screening: results from an Italian experience. J Med Screen 2003, 10:134-138.
3. Gori S., Clavarezza M., Siena S., Foglietta J., Tarenzi E., Giordano M., et al. Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study. BMC Cancer 2012, 12:158.
4. Kolben T., Harbeck N., Wuerstlein R., Schubert-Fritschle G., Bauerfeind I., Schrodi S., et al. Endocrine sensitivity is decisive for patient outcome in small node negative breast cancers (BC) (pT1a, b) - results from the Munich Cancer Registry. Breast 2015, 24:24-31.
5. Joensuu H., Pylkkanen L., Toikkanen S. Late mortality from pT1N0M0 breast carcinoma. Cancer 1999, 85:2183-2189.
6. Vaz-Luis I., Ottesen R.A., Hughes M.E., Mamet R., Burstein H.J., Edge S.B., et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol 2014, 32:2142-2150.
7. Paplomata E., Nahta R., O'Regan R.M. Systemic therapy for early-stage HER2-pòositive breast cancers: time for a less-is-more approach?. Cancer 2015, 121:517-526.
8. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
9. Banerjee S., Smith I.E. Management of small HER2-positive breast cancers. Lancet Oncol 2010, 11:1193-1199.
10. Albanell J., Ciruelos E.M., Lluch A., Muñoz M., Rodríguez C.A. Trastuzumab in small tumours and in elderly women. Cancer Treat Rev 2014, 40:41-47.
11. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
12. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354:809-820.
13. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: breast cancer. 2015. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp-site.
14. Ross J.S., Slodkowska E.A., Symmans W.F., Pusztai L., Raydin P.M., Hortobagyi G.N., et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14:320-368.
15. Rosen P.R., Groshen S., Saigo P.E., Kinne D.W., Hellman S. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 1989, 7:355-366.
16. Arnesson L.G., Smeds S., Fagerberg G. Recurrence-free survival in patients with small breast cancer. An analysis of cancers 10 mm or less detected clinically and by screening. Eur J Surg 1994, 160:271-276.
17. Rom J., Schumacher C., Gluz O., et al. Association of HER2 overexpression and prognosis in small (T1N0) primary breast cancers. Breast Care (Basel) 2013, 8:208-214.
18. Hanrahan E.O., Gonzalez-Angulo A.M., Giordano S.H., Rouzier R., Broglio K.R., Hortobagyi G.N., et al. Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol 2007, 25:4952-4960.
19. Kwon J.H., Kim Y.J., Lee K.W., Oh D.Y., Park S.Y., Kim J.H., et al. Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less. BMC Cancer 2010, 10:557.
20. Theriault R.L., Litton J.K., Mittendorf E.A., Chen H., Meric-Bernstam F., Chavez-Macgregor M., et al. Age and survival estimates in patients who have node negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer 2011, 11(5):325-331.
21. Livi L., Meattini I., Saieva C., Franzese C., Di Cataldo V., Greto D., et al. Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer. Cancer 2012, 118(13):3236-3243.
22. Rouanet P., Roger P., Rousseau E., Thibault S., Romieu G., Mathieu A., et al. HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort. Cancer Med 2014, 3:134-142.
23. Curigliano G., Viale G., Bagnardi V., Fumagalli L., Locatelli M., Rotmensz N., et al. Clinical relevance of HER overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009, 27:5693-5699.
24. Sonnenblick A., Fumagalli D., Azim H.A., Sotiriou C., Piccart M. New strategies in breast cancer: the significance of molecular subtypes in systemic adjuvant treatment for small T1a, bN0M0 tumors. Clin Cancer Res 2014, 20:6242-6246.
25. Fehrenbacher L., Capra A.M., Quesenberry C.P., Fulton R., Shiraz P., Habel L.A. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol 2014, 32:2151-2158.
26. Verschraegen C., Vinh-Hung V., Cserni G., Gordon R., Royce M.E., Vlastos G., et al. Modeling the effect of tumor size in early breast cancer. Ann Surg 2005, 241:309-318.
27. Joensuu H., Isola J., Lundin M., Salminen T., Holli K., Kataja V., et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003, 9:923-930.
28. Chia S.K., Speers C.H., Bryce C.J., Hayes M.M., Olivotto I.A. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 2004, 22:1630-1637.
29. Gamucci T., Vaccaro A., Ciancola F., Pizzuti L., Sperduti I., Moscetti L., et al. Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis. J Cancer Res Clin Oncol 2013, 139:853-860.
30. Colleoni M., Rotmensz N., Peruzzotti G., Maisonneuve P., Viale G., Renne G., et al. Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. Ann Oncol 2004, 15:1633-1639.
31. Chia S., Norris B., Speers C., Cheang M., Gilks B., Gown A.M., et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008, 26:5697-5704.
32. Gonzalez-Angulo A.M., Litton J.K., Broglio K.R., et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009, 27:5700-5706.
33. Amar S., McCullough A.E., Tan W., Geiger X.J., Boughey J.C., McNeil R.B., et al. Prognosis and outcome of small (≤1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist 2010, 15:1043-1049.
34. Albert J.M., Gonzalez-Angulo A.M., Guray M., Sahin A., Strom E.A., Tereffe W., et al. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a, bN0 breast cancer. Int J Radiat Oncol Biol Phys 2010, 77:1296-1302.
35. Park Y.H., Kim S.T., Cho E.Y., Choi Y.L., Ok O.N., Baek H.J., et al. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?. Breast Cancer Res Treat 2010, 119:653-661.
36. Cancello G., Maisonneuve P., Rotmensz N., Viale G., Mastropasqua M.G., Pruneri G., et al. Prognosis in women with small (T1mic, T1a, T1b) node negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat 2011, 127:713-720.
37. Horio A., Fujita T., Hayashi H., Hattori M., Kondou N., Yamada M., et al. High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers. Int J Clin Oncol 2012, 17:131-136.
38. Gorshein E., Klein P., Boolbol S.K., Shao T. Clinical significance of HER2-positive and triple-negative status in small (≤1 cm) node-negative breast cancer. Clin Breast Cancer 2014, 14:309-314.
39. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
40. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726-3734.
41. Torrisi R., Garcia-Etienne C.A., Losurdo A., et al. Potential impact of the 70-gene signature in the choice of adjuvant systemic treatment for ER positive, HER2 negative tumors: a single institution experience. Breast 2013, 22:419-424.
42. Sparano J.A., Gray R.J., Makower D.F., Pritchard K.I., Albain K.S., Hayes D.F., et al. Expression Assay in Breast Cancer. N Engl J Med 2015, Epub ahead of print.
43. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
44. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
45. O'Sullivan C.C., Bradbury I., Campbell C., Spielmann M., Perez E.A., Joensuu H., et al. Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2-positive early breast cancer and tumors ≤2 cm: a meta-analysis of the randomized trastuzumab trials. J Clin Oncol 2015, 33:2600-2608.
46. Rodrigues M.J., Peron J., Frénel J.-S., Vano Y.-A., Wassermann J., Debled M., et al. Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series. Ann Oncol 2012, 1-8.
47. Zhou Q., Yin W., Du Y., Lu J. For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures. PLoS ONE 2014, 9:e83646.
48. Tognela A., Beith J., Kiely B., Bastick P., Lynch J., Descallar J., et al. Small HER2-positive breast cancer: should size affect adjuvant treatment?. Clin Breast Cancer 2015, 15:277-284.
49. Olszewski A.J., Migdady Y., Boolbol S.K., Klein P., Boachie-Adjei K., Sakr B.J., et al. Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study. Breast Cancer Res Treat 2013, 138:215-223.
50. Migdady Y., Sakr B.J., Sikow W.M., Olszewski A.J. Adjuvant chemotherapy in T1a/bN0 HER2-positive or triple-negative breast cancers: application and outcomes. Breast 2013, 22:793-798.
51. Senkus E., Kyriakides S., Ohno S., Penault-Llorca F., Poortmans P., Rutgers E., et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015, 26(Suppl.):v8-v30.
52. Vaz Duarte Luis I.M., Hughes M.E., Cronin A., Rugo H.S., Edge S.B., Moy B., et al. Emerging trends in type of chemotherapy received among patients with stage I breast cancer. J Clin Oncol 2014, (Suppl.):32. [abstr 522:5s].
53. Gori S., Inno A., Fiorio E., Foglietta J., Ferro A., Gulisano M., et al. The Promher study: an observational italian study on adjuvant therapy for HER2-positive, pT1a-b pN0 breast cancer. PloS ONE 2015, 10:e0136731.
54. Tolaney S.M., Barry W.T., Dang C.T., Yardley D.A., Moy B., Marcom P.K., et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015, 372:134-141.
55. Rimawi M.F., Niravath P.A., Wang T., Rexer B., Forero A., Wolff A.C., et al. TBCRC023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer. SABCS 2014, [abstr:S6-02].
56. Gianni L., Pienkowski T., Im Y.H., Roman L., Tseng L.M., Liu M.C., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:25-32.
57. de Azambuja E., Holmes A.P., Piccart-Gebhart M., Holmes E., Di Cosimo S., Swaby R.F., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 2014, 15:1137-1146.
58. ClinicalTrials.gov: T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial). https://clinicaltrials.gov/ct2/show/NCT01853748.
59. Carey L., Barry W.T., Pitcher B., Hoadley K.A., Chaeng M.C.U., Anders C.K., et al. Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. J Clin Oncol 2014, 32(Suppl. 5). [abstr 506].
60. Nelson H.D., Tyne K., Naik A., Bougatsos C., Chan B.K., Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2009, 151:727-737.
61. Bucchi L., Ravaioli A., Foca F., Colamartini A., Falcini F., Naldoni C., et al. Incidence of interval breast cancers after 650,000 negative mammographies in 13 Italian health districts. J Med Screen 2008, 15:30-35.
62. Porter P.L., El Bastawissi A.Y., Mandelson M.T., Lin M.G., Khalid N., Watney E.A., et al. Breast tumors characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 1999, 91:2020-2028.
63. Musolino A., Michiara M., Conti G.M., Boggiani D., Zatelli M., Palleschi D., et al. HER2 status and interval breast cancer detection in a population-based cancer registry study. J Clin Oncol 2012, 30:2362-2368.
64. Domingo L., Sala M., Servitja S., Corominas J.M., Ferrer F., Martinez J., et al. Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona Spain. Cancer Causes Control 2010, 21:1155-1164.
65. Kirsh V.A., Chiarelli A.M., Edwards S.A., O'Malley F.P., Shumak R.S., Yaffe M.J., et al. Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program. J Natl Cancer Inst 2011, 103:942-950.
66. Domingo L., Salas D., Zubizarreta R., Baré M., Sarriugarte G., Barata T., et al. Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain. Breast Cancer Res 2014, 16:R3.
67. Holm J., Humphreys K., Li J., Ploner A., Cheddad A., Eriksson M., et al. Risk factors and tumor characteristics of interval cancers by mammographic density. J Clin Oncol 2015, 331030-331037.
68. Musolino A., Michiara M., Boggiani D., Sikokis A., Rimanti A., Pellegrino B., et al. Prognostic impact of HER2 overexpression/amplification in women with pT1a N0 M0 breast cancer with known from a multicenter population-based cancer registry study. J Clin Oncol 2015, 33(Suppl.). [abstr 594].